Real-world use of TAR-200 for non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how patients with non-muscle invasive bladder cancer are using TAR-200 in everyday medical care. It aims to understand treatment patterns and outcomes outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-muscle invasive bladder cancer (cancer that has not spread into the bladder muscle).
- You have started your first dose of TAR-200 within the past 6 weeks as part of your regular care.
- If you could become pregnant, you must follow the contraceptive guidelines provided with TAR-200 and talk to your doctor about birth control.
- You must be willing to sign a consent form to participate.
- You cannot be in another clinical trial for bladder cancer right now.
- You cannot have had more than 2 doses of TAR-200 before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
This trial tests a combination of an immunotherapy drug (toripalimab) with or without two chemotherapy drugs placed directly into the bladder (gemcitabine and mitomycin C). It is for people whose high-risk bladder cancer did not respond to or could not tolerate BCG treatment.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
Hear when a new Non-Muscle Invasive Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.